Safety data sheet. GHS / OSHA HCS 2012 format, 16 sections. Issued by Epic Peptides Lab for the catalogue items listed in Section 1.

Epic Peptides Lab

Safety data sheet · capsules

Epic Peptides Lab · USA

Document number: PL-SDS-142
Revision: 1.0 · 2026-10-03

S-23

capsules

WARNING

1Identification

Product Identifier

S-23

Document Number

PL-SDS-142

Catalogue Items Covered

Id
8660
Name
S-23 10mg Capsules
Sku
PL-S23-10MG-CAP

Recommended Use

Laboratory research use by trained personnel.

Restrictions On Use

Not for human or veterinary use.

Supplier / Distributor

Epic Peptides Lab, USA

Telephone

+1 (787) 468-5291

info@epicpeptideslab.com

2Hazard(s) identification

Classification

Reproductive toxicity — Category 2 — H361

Label Elements

Pictograms: GHS08
Signal: Warning
Hazard statements: H361 Suspected of damaging fertility or the unborn child.
Precautionary statements: P201 Obtain special instructions before use.

P202 Do not handle until all safety precautions have been read and understood.

P280 Wear protective gloves, protective clothing and eye protection.

P308+P313 IF exposed or concerned: Get medical advice/attention.

P405 Store locked up.

P501 Dispose of contents and container to an approved waste disposal plant in accordance with local, state and federal regulations.

Signal Word

Warning

Other Hazards

No data available.

3Composition / information on ingredients

Description

Hard gelatin capsules containing the active substance blended with microcrystalline cellulose, packed in a sealed bottle.

Composition

Name
S-23
Full
S-23, selective androgen receptor modulator
Cas
1010396-29-8
Formula
C18H13ClF4N2O3
Conc
2.5% w/w of capsule contents (nominal)
Qty
10 mg per capsule
Hazards
- Acute toxicity, oral — Category 4 — H302
- Hazardous to the aquatic environment, long-term — Category 4 — H413
- Reproductive toxicity — Category 2 — H361
Name
Microcrystalline cellulose
Full
Microcrystalline cellulose (capsule filler)
Cas
9004-34-6
Formula
(C6H10O5)n
Conc
balance of capsule contents
Name
Gelatin
Full
Gelatin (capsule shell)
Cas
9000-70-8
Conc
capsule shell

4First-aid measures

First Aid Measures

Inhalation: Move the person to fresh air and keep comfortable for breathing. If breathing is difficult or symptoms persist, call a POISON CENTER or doctor.
Skin: Take off contaminated clothing. Wash the skin with plenty of soap and water. If irritation or a rash develops, get medical advice.
Eyes: Rinse cautiously with water for several minutes. Remove contact lenses if present and easy to do; continue rinsing. If eye irritation persists, get medical advice.
Ingestion: Rinse mouth. Do not induce vomiting. Call a POISON CENTER or doctor if you feel unwell.
General: If exposed or concerned, get medical advice. Show this safety data sheet to the doctor. Pregnant or nursing laboratory staff should avoid exposure.

Most Important Symptoms And Effects

No specific symptoms are known. Pharmacologically active material: systemic effects consistent with its mechanism of action are possible after accidental injection, ingestion or absorption.

Likely Routes Of Exposure

Ingestion; inhalation of dust and skin/eye contact if capsules are opened.

5Fire-fighting measures

Fire Fighting Information: Combustible organic solid; capsule contents may form combustible dust if dispersed in bulk.

6Accidental release measures

Spill And Clean Up Procedures: Collect intact capsules. Dampen any spilled powder with water, wipe up with absorbent material and place in a sealed container for disposal.

7Handling and storage

Safe Handling: Do not open or crush capsules unless required for an experiment; if capsule contents are handled as a powder, avoid generating dust and weigh inside a ventilated enclosure. Wash hands after handling.
Safe Storage: Store at room temperature (15–25 °C) in the tightly closed original container, dry and protected from light.
Storage Temperature: 15–25 °C, dry, protected from light
Incompatible Materials: Oxidizing agents (Cayman)

8Exposure controls / personal protection

Occupational Exposure Limits: Microcrystalline cellulose: OSHA PEL 15 mg/m³ (total dust), 5 mg/m³ (respirable fraction); ACGIH TLV 10 mg/m³ (as cellulose).

No occupational exposure limits have been established for the active ingredient(s).
Exposure Controls And PPE: No data available.

9Physical and chemical properties

Physical State

Solid

Appearance

Hard gelatin capsules containing a white to off-white powder

Properties

Odor: Characteristic (Cayman)
Ph: Not applicable (solid)
Melting: Undetermined (Cayman); not documented (ChemicalBook)
Boiling: Undetermined
Flash: Not applicable (non-flammable solid); combustible organic material
Vapour: Negligible (solid)
Density: No data available (bulk density of lyophilized cake is low)
Solubility: Cayman: DMF 20 mg/ml; DMSO 14 mg/ml; ethanol 10 mg/ml; DMF:PBS (1:4) 0.2 mg/ml. ChemicalBook: slightly soluble in chloroform and methanol. Practically insoluble in water
Logp: No data available (lipophilic aryl-propionamide)
Decomp: No data available; peptides decompose above about 200 °C
Other: Not flammable. CAS 1010396-29-8; C18H13ClF4N2O3, MW 416.8; halogenated (Cl, F) non-steroidal SARM

10Stability and reactivity

Stability And Reactivity

Reactivity: No dangerous reactions known; no decomposition if used according to specifications (Cayman)
Incompatible: Oxidizing agents (Cayman)
Decomposition: Carbon dioxide, carbon monoxide, hydrogen chloride gas, hydrogen fluoride, nitrogen oxides (Cayman) - halogenated acid gases on combustion
Conditions To Avoid: No further relevant information available; store -20 °C, dry, dark

Conditions To Avoid

No data available.

Incompatible Materials

No data available.

11Toxicological information

Toxicological Information: Acute toxicity, oral
No LD50 in either SDS; classified Acute Tox. 4 oral (H302) by Cayman - estimate based, no value quoted

Acute toxicity, dermal
No data available

Acute toxicity, inhalation
No data available

Skin corrosion/irritation
No irritant effect (Cayman); no data (ChemicalBook)

Serious eye damage/irritation
No irritating effect (Cayman)

Respiratory or skin sensitisation
No sensitizing effects known (Cayman)

Germ cell mutagenicity
No data available

Carcinogenicity
Not listed by IARC, NTP or OSHA-Ca

Reproductive toxicity
No data available in SDSs; however S-23 is a potent androgen-receptor agonist studied as a reversible male contraceptive because it suppresses spermatogenesis and gonadotropins in rats - a clear reproductive-toxicity concern (see notes)

STOT, single exposure
No data available

STOT, repeated exposure
No data available

Aspiration hazard
No data available
Routes Of Exposure: Ingestion; inhalation of dust and skin/eye contact if capsules are opened.
Symptoms: No specific symptoms are known. Pharmacologically active material: systemic effects consistent with its mechanism of action are possible after accidental injection, ingestion or absorption.

12Ecological information

Ecological Information: Cayman classifies Aquatic Chronic 4 (H413, may cause long lasting harmful effects to aquatic life) though it gives no measured aquatic toxicity, persistence or bioaccumulation data; halogenated lipophilic compound - avoid release to the environment.

13Disposal considerations

Disposal Guidance: No data available.

14Transport information

Transport Classification

Note: Not regulated as a dangerous good for transport by road (DOT 49 CFR), air (IATA/ICAO) or sea (IMDG). Not a marine pollutant. Ship refrigerated or frozen as required by Section 7; the coolant (dry ice, UN 1845) is regulated when used.

15Regulatory information

Regulatory Information

Tsca: Substance is not listed (Cayman, ChemicalBook)
Carcinogen Listings: Not listed by IARC, NTP, OSHA or EPA
Dea: Not a DEA-scheduled substance (SARMs are not federally scheduled; a SARMs Control Act has been proposed in Congress but verify current status). Not an approved drug; FDA has warned that SARMs are unapproved drugs that may not be sold as dietary supplements
Other: Not listed on EINECS/EC inventory, TSCA, IECSC, KECL, PICCS, NZIoC (ChemicalBook). Not listed under SARA or as a HAP. WADA remark: S-23 is explicitly named on the WADA Prohibited List (S1.2 Other anabolic agents - SARMs).

Carcinogen Listings

No data available.

16Other information

Revision: October 3, 2026
Sources Consulted: Cayman Chemical

ChemicalBook

Spectrum Chemical

Sigachi Industries

Parchem

Fisher Scientific / Acros Organics

Electron Microscopy Sciences
Confidence: high
Additional Information: Selective androgen receptor modulator (SARM). No supplier SDS assigns a reproductive classification, but SARMs act on the androgen receptor, suppress gonadotropins and spermatogenesis in animal and human studies and are prohibited at all times under WADA class S1.2. PrymaLab therefore self-classifies the substance as Reproductive toxicity Category 2 (H361) by expert judgement.

Back to SDS list